Literature DB >> 32841911

Rationally designed rapamycin-encapsulated ZIF-8 nanosystem for overcoming chemotherapy resistance.

Mengran Xu1, Yi Hu2, Weiping Ding2, Fenfen Li2, Jun Lin3, Min Wu4, Jingjing Wu4, Long-Ping Wen5, Bensheng Qiu6, Peng-Fei Wei7, Ping Li8.   

Abstract

Zeolitic imidazolate framework-8 (ZIF-8) nanoparticles are widely reported as a pH-sensitive drug delivery carrier with high loading capacity for tumor therapy. However, the mechanism of intracellular corrosion of ZIF-8 and the corresponding biological effects especially for autophagy response have been rarely reported. Herein, the as-synthesized ZIF-8 was demonstrated to induce mTOR independent and pro-death autophagy. Interestingly, the autophagic process participated in the corrosion of ZIF-8. Subsequently, zinc ion release and the generation of reactive oxygen species due to its corrosion in the acidic compartments were directly responsible for tumor cell killing. In addition, ZIF-8 could sensitize tumor cells to chemotherapy by switching cytoprotective to death promoting autophagy induced by doxorubicin. The mTOR signaling pathway activation was demonstrated to restrict tumor chemotherapy efficiency. Hence, a combined platform rapamycin encapsulated zeolitic imidazolate frameworks (Rapa@ZIF-8) was constructed and demonstrated a more significant chemo-sensitized effect relative to ZIF-8 nanoparticles or rapamycin treatment alone. Lastly, the combined administration of Rapa@ZIF-8 and doxorubicin exhibited an outstanding synergistic antitumor effect without any obvious toxicity to the major organs of mice. Collectively, the optimized nanoplatform, Rapa@ZIF-8, provides a proof of concept for intentionally interfering mTOR pathway and utilizing the switch of survival-to death-promoting autophagy for adjunct chemotherapy.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Doxorubicin; Mammalian target of rapamycin (mTOR); Overcoming drug resistance; Pro-death autophagy; Zeolitic imidazolate Framework-8 (ZIF-8)

Mesh:

Substances:

Year:  2020        PMID: 32841911     DOI: 10.1016/j.biomaterials.2020.120308

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  6 in total

1.  Construction and evaluation of detachable bone-targeting MOF carriers for the delivery of proteasome inhibitors.

Authors:  Hongbing Yang; Zhenyan Yu; Shuaishuai Ji; Jie Yan; Lei Han; Yang Liu; Yanjuan Wang; Yimin Niu; Qiang Huo; Ming Xu
Journal:  RSC Adv       Date:  2022-05-16       Impact factor: 4.036

2.  Augmented EPR effect post IRFA to enhance the therapeutic efficacy of arsenic loaded ZIF-8 nanoparticles on residual HCC progression.

Authors:  Xuehua Chen; Yongquan Huang; Hui Chen; Ziman Chen; Jiaxin Chen; Hao Wang; Dan Li; Zhongzhen Su
Journal:  J Nanobiotechnology       Date:  2022-01-15       Impact factor: 9.429

3.  Exosome-functionalized magnesium-organic framework-based scaffolds with osteogenic, angiogenic and anti-inflammatory properties for accelerated bone regeneration.

Authors:  Yue Kang; Chang Xu; Ling'ao Meng; Xufeng Dong; Min Qi; Daqing Jiang
Journal:  Bioact Mater       Date:  2022-02-18

4.  pH-responsive curcumin-based nanoscale ZIF-8 combining chemophotodynamic therapy for excellent antibacterial activity.

Authors:  Xiaofeng Meng; Jingwei Guan; Shanshan Lai; Liming Fang; Jianyu Su
Journal:  RSC Adv       Date:  2022-03-30       Impact factor: 3.361

5.  Lanthanide europium MOF nanocomposite as the theranostic nanoplatform for microwave thermo-chemotherapy and fluorescence imaging.

Authors:  Lirong Zhao; Wei Zhang; Qiong Wu; Changhui Fu; Xiangling Ren; Kongpeng Lv; Tengchuang Ma; Xudong Chen; Longfei Tan; Xianwei Meng
Journal:  J Nanobiotechnology       Date:  2022-03-15       Impact factor: 10.435

Review 6.  Nanoscale Zeolitic Imidazolate Framework (ZIF)-8 in Cancer Theranostics: Current Challenges and Prospects.

Authors:  Hongxin Xie; Xinyu Liu; Zhengrong Huang; Liexi Xu; Rui Bai; Fajian He; Mengqin Wang; Linzhi Han; Zhirong Bao; Yuzhou Wu; Conghua Xie; Yan Gong
Journal:  Cancers (Basel)       Date:  2022-08-15       Impact factor: 6.575

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.